drugset / Trial / NCT05185583

Methylphenidate in Childhood Apraxia of Speech

NCT05185583

Phase 2 Completed 18 enrolled Murdoch Childrens Research Institute
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this study is to describe the possible effects of methylphenidate (MPH) on speech intelligibility in children with childhood apraxia of speech (CAS) aged 6-12 years. This outcome will be compared between MPH intake and placebo intake.

Timeline

Start
2022-03-14
Primary completion
2025-10-27
Completion
2025-10-27

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Methylphenidate Small molecule 20 mg
Subject Methylphenidate Small molecule 30 mg
Subject Methylphenidate Small molecule 40 mg